173 related articles for article (PubMed ID: 12862359)
1. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.
Mikolajczyk SD; Rittenhouse HG
Keio J Med; 2003 Jun; 52(2):86-91. PubMed ID: 12862359
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Luque P; Corral JM; Augé JM; Coca F
Anticancer Res; 2007; 27(1B):607-10. PubMed ID: 17348449
[TBL] [Abstract][Full Text] [Related]
5. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Mikolajczyk SD; Catalona WJ; Evans CL; Linton HJ; Millar LS; Marker KM; Katir D; Amirkhan A; Rittenhouse HG
Clin Chem; 2004 Jun; 50(6):1017-25. PubMed ID: 15054080
[TBL] [Abstract][Full Text] [Related]
6. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
[TBL] [Abstract][Full Text] [Related]
8. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
Catalona WJ; Bartsch G; Rittenhouse HG; Evans CL; Linton HJ; Amirkhan A; Horninger W; Klocker H; Mikolajczyk SD
J Urol; 2003 Dec; 170(6 Pt 1):2181-5. PubMed ID: 14634374
[TBL] [Abstract][Full Text] [Related]
9. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis.
Sokoll LJ; Chan DW; Mikolajczyk SD; Rittenhouse HG; Evans CL; Linton HJ; Mangold LA; Mohr P; Bartsch G; Klocker H; Horninger W; Partin AW
Urology; 2003 Feb; 61(2):274-6. PubMed ID: 12597929
[TBL] [Abstract][Full Text] [Related]
10. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.
Hori S; Blanchet JS; McLoughlin J
BJU Int; 2013 Oct; 112(6):717-28. PubMed ID: 22759214
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
Parwani AV; Marlow C; Demarzo AM; Mikolajczyk SD; Rittenhouse HG; Veltri RW; Chan TY
Am J Surg Pathol; 2006 Oct; 30(10):1231-6. PubMed ID: 17001152
[TBL] [Abstract][Full Text] [Related]
12. [Usefulness of PSA and its fractions in the diagnosis of prostate cancer].
Filella X; Truan D; Alcover J; Molina R; Luque P; Coca F; Ballesta AM
Med Clin (Barc); 2004 Feb; 122(7):241-4. PubMed ID: 15012870
[TBL] [Abstract][Full Text] [Related]
13. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness.
Sokoll LJ; Sanda MG; Feng Z; Kagan J; Mizrahi IA; Broyles DL; Partin AW; Srivastava S; Thompson IM; Wei JT; Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1193-200. PubMed ID: 20447916
[TBL] [Abstract][Full Text] [Related]
14. [Recent advances in proPSA on early detection in prostate cancer].
Zhu PY; Hong P; Huang YF
Zhonghua Nan Ke Xue; 2005 Dec; 11(12):944-6. PubMed ID: 16398372
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer.
Naya Y; Fritsche HA; Bhadkamkar VA; Mikolajczyk SD; Rittenhouse HG; Babaian RJ
Urol Oncol; 2005; 23(1):16-21. PubMed ID: 15885578
[TBL] [Abstract][Full Text] [Related]
16. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
Canto EI; Singh H; Shariat SF; Lamb DJ; Mikolajczyk SD; Linton HJ; Rittenhouse HG; Kadmon D; Miles BJ; Slawin KM
Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
[TBL] [Abstract][Full Text] [Related]
17. [Molecular forms of PSA].
Benchikh El Fegoun A; Villers A
Prog Urol; 2007 Apr; 17(2):165-71. PubMed ID: 17489311
[TBL] [Abstract][Full Text] [Related]
18. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
19. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.
Linton HJ; Marks LS; Millar LS; Knott CL; Rittenhouse HG; Mikolajczyk SD
Clin Chem; 2003 Feb; 49(2):253-9. PubMed ID: 12560348
[TBL] [Abstract][Full Text] [Related]
20. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics.
Miller MC; O'Dowd GJ; Partin AW; Veltri RW
Urology; 2001 Jun; 57(6):1105-11. PubMed ID: 11377319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
